Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor.
immunotherapy
translational medical research
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
accepted:
06
12
2022
entrez:
21
12
2022
pubmed:
22
12
2022
medline:
24
12
2022
Statut:
ppublish
Résumé
With the increased use of immune checkpoint inhibitors (ICIs), side effects and toxicity are a great concern. Anaphylaxis has been identified as a potential adverse event induced by ICIs. Anaphylaxis is a life-threatening medical emergency. However, the mechanisms and factors that can potentially influence the incidence and severity of anaphylaxis in patients with cancer remain unclear. Healthy, murine colon 26, CT26, breast 4T1, EMT6, and renal RENCA tumor-bearing mice were treated with an anti-PD-L1 antibody (clone 10F.9G2). Symptoms of anaphylaxis were evaluated along with body temperature and mortality. The amounts of antidrug antibody and platelet-activating factor (PAF) in the blood were quantified via ELISA and liquid chromatography-mass spectrometry (LC-MS/MS). Immune cells were analyzed and isolated using a flow cytometer and magnetic-activated cell sorting, respectively. Repeated administration of the anti-PD-L1 antibody 10F.9G2 to tumor-bearing mice caused fatal anaphylaxis, depending on the type of tumor model. After administration, antidrug immunoglobulin G (IgG), but not IgE antibodies, were produced, and PAF was released as a chemical mediator during anaphylaxis, indicating that anaphylaxis was caused by an IgG-dependent pathway. Anaphylaxis induced by 10F.9G2 was treated with a PAF receptor antagonist. We identified that neutrophils and macrophages were PAF-producing effector cells during anaphylaxis, and the tumor-bearing models with increased numbers of neutrophils and macrophages showed lethal anaphylaxis after treatment with 10F.9G2. Depletion of both neutrophils and macrophages using clodronate liposomes prevented anaphylaxis in tumor-bearing mice. Thus, increased numbers of neutrophils and macrophages associated with cancer progression may be risk factors for anaphylaxis. These findings may provide useful insights into the mechanism of anaphylaxis following the administration of immune checkpoint inhibitors in human subjects.
Sections du résumé
BACKGROUND
With the increased use of immune checkpoint inhibitors (ICIs), side effects and toxicity are a great concern. Anaphylaxis has been identified as a potential adverse event induced by ICIs. Anaphylaxis is a life-threatening medical emergency. However, the mechanisms and factors that can potentially influence the incidence and severity of anaphylaxis in patients with cancer remain unclear.
METHODS
Healthy, murine colon 26, CT26, breast 4T1, EMT6, and renal RENCA tumor-bearing mice were treated with an anti-PD-L1 antibody (clone 10F.9G2). Symptoms of anaphylaxis were evaluated along with body temperature and mortality. The amounts of antidrug antibody and platelet-activating factor (PAF) in the blood were quantified via ELISA and liquid chromatography-mass spectrometry (LC-MS/MS). Immune cells were analyzed and isolated using a flow cytometer and magnetic-activated cell sorting, respectively.
RESULTS
Repeated administration of the anti-PD-L1 antibody 10F.9G2 to tumor-bearing mice caused fatal anaphylaxis, depending on the type of tumor model. After administration, antidrug immunoglobulin G (IgG), but not IgE antibodies, were produced, and PAF was released as a chemical mediator during anaphylaxis, indicating that anaphylaxis was caused by an IgG-dependent pathway. Anaphylaxis induced by 10F.9G2 was treated with a PAF receptor antagonist. We identified that neutrophils and macrophages were PAF-producing effector cells during anaphylaxis, and the tumor-bearing models with increased numbers of neutrophils and macrophages showed lethal anaphylaxis after treatment with 10F.9G2. Depletion of both neutrophils and macrophages using clodronate liposomes prevented anaphylaxis in tumor-bearing mice.
CONCLUSIONS
Thus, increased numbers of neutrophils and macrophages associated with cancer progression may be risk factors for anaphylaxis. These findings may provide useful insights into the mechanism of anaphylaxis following the administration of immune checkpoint inhibitors in human subjects.
Identifiants
pubmed: 36543377
pii: jitc-2022-005657
doi: 10.1136/jitc-2022-005657
pmc: PMC9772690
pii:
doi:
Substances chimiques
Immunoglobulin G
0
Immune Checkpoint Inhibitors
0
Platelet Activating Factor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Ann Allergy Asthma Immunol. 2021 Jun;126(6):623-629
pubmed: 33781937
J Exp Med. 2007 Jun 11;204(6):1463-74
pubmed: 17548519
J Allergy Clin Immunol. 2002 Sep;110(3):341-8
pubmed: 12209078
J Pharmacol Exp Ther. 1987 Jul;242(1):263-8
pubmed: 3612533
J Crohns Colitis. 2012 Feb;6(1):108-11
pubmed: 22261535
Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855
pubmed: 30482962
J Allergy Clin Immunol. 2016 Jun;137(6):1674-1680
pubmed: 27130857
Eur J Immunol. 2011 Mar;41(3):749-59
pubmed: 21287554
Oncologist. 2016 Oct;21(10):1260-1268
pubmed: 27440064
Cell Immunol. 2014 May-Jun;289(1-2):97-105
pubmed: 24751884
World Allergy Organ J. 2020 Oct 30;13(10):100472
pubmed: 33204386
J Investig Allergol Clin Immunol. 2016;26(2):73-82; quiz 2p following 83
pubmed: 27164622
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
Blood. 2014 Apr 3;123(14):2172-80
pubmed: 24558202
J Allergy Clin Immunol. 2017 Jan;139(1):269-280.e7
pubmed: 27246523
Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12413-8
pubmed: 21746933
Cancer Res. 2013 Jan 1;73(1):395-405
pubmed: 23108143
Future Oncol. 2021 Jul;17(19):2545-2558
pubmed: 33783228
AAPS J. 2014 May;16(3):488-98
pubmed: 24682765
Immunity. 2008 Apr;28(4):581-9
pubmed: 18342553
J Allergy Clin Immunol. 2017 Aug;140(2):335-348
pubmed: 28780941
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32041818
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Oncoimmunology. 2018 Feb 20;7(4):e1413520
pubmed: 29632731
Clin Cancer Res. 2013 Mar 1;19(5):1035-43
pubmed: 23460534
J Immunol. 2009 May 1;182(9):5693-701
pubmed: 19380816
Cancer Cell. 2015 Sep 14;28(3):285-95
pubmed: 26373277
Int J Mol Sci. 2019 Dec 16;20(24):
pubmed: 31888216
Anal Bioanal Chem. 2014 May;406(13):3111-8
pubmed: 24682147
Biochem Biophys Res Commun. 2018 Sep 26;504(1):270-276
pubmed: 30172372
J Clin Invest. 2006 Mar;116(3):833-41
pubmed: 16498503
Sci Rep. 2019 Aug 7;9(1):11472
pubmed: 31391510
PLoS One. 2014 Aug 21;9(8):e104453
pubmed: 25144454
J Allergy Clin Immunol. 2007 Sep;120(3):506-15; quiz 516-7
pubmed: 17765751
J Immunol. 2007 Jul 15;179(2):977-83
pubmed: 17617589
J Clin Invest. 2011 Apr;121(4):1484-96
pubmed: 21436586